A real-world pharmacovigilance analysis for agalsidase beta: findings from the FDA adverse event reporting database
The FAERS database analysis of agalsidase beta AEs identified a significant number of cardiovascular, renal, and cerebrovascular system-related reports. While agalsidase beta is generally well-tolerated, the study underscores the necessity for gender-specific treatment approaches due to the higher incidence of certain AEs in males.
Authors
- Di Li (ORCID: https://orcid.org/0000-0003-1267-7038)
- Juyi Li (ORCID: https://orcid.org/0000-0002-5141-4655)
- Hou‐Hong Li
- Aiping Deng (ORCID: https://orcid.org/0000-0003-2119-7570)
- Wen-Long Xie
Institutions
- Central Hospital of Wuhan (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1080/14740338.2024.2446429
- Citations
- 3
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.98